Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation.

Author:

Wang Z1,Pagé P1,Nattel S1

Affiliation:

1. Department of Medicine, Montreal Heart Institute, Quebec, Canada.

Abstract

Class Ic antiarrhythmic drugs are effective in the treatment of atrial fibrillation, but their mechanism of action is unknown. In previous work, we have found that flecainide causes tachycardia-dependent increases in atrial action potential duration (APD) and effective refractory period (ERP) by reducing APD accommodation to heart rate. The present study was designed to evaluate the efficacy and mechanisms of action of flecainide in an experimental model of sustained atrial fibrillation (AF). AF was produced by a brief burst of atrial pacing in the presence of vagal stimulation and persisted spontaneously until vagal stimulation was stopped. The actions of flecainide at two dose levels were compared with those of isotonic glucose placebo in each dog, with a randomized order of blinded drug administration. Flecainide terminated AF in all 16 dogs, while glucose was effective in none (p less than 0.0001). Flecainide increased atrial ERP and reduced conduction velocity in a tachycardia-dependent manner. Doses of flecainide that converted AF resulted in larger changes in ERP than in conduction velocity, increasing the minimum path-length capable of supporting reentry (wavelength). In addition, flecainide reduced regional heterogeneity in ERP and wavelength, an action opposite that of vagal stimulation. Atrial epicardial mapping with a 112-electrode atrial array was used to study the mechanism of flecainide action on AF. Under control conditions, multiple small zones of reentry coexisted. Flecainide progressively increased the size of reentry circuits, decreased their number, and slowed the frequency of atrial activation until the arrhythmia finally terminated; all changes were compatible with an increase in wavelength. We conclude that flecainide terminates atrial fibrillation in this experimental model by causing tachycardia-dependent increases in atrial ERP, which increase the wavelength at the rapid rates characteristic of AF to the point that the arrhythmia can no longer sustain itself.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Reference74 articles.

1. Herre JM Scheinman MM: Supraventricular tachycardia in Parmley WW Chatterjee K Cheitlin MD Karliner JS Rapaport E Scheinman MM (eds): Cardiology: Physiology Pharmacology Diagnosis. Philadelphia J.B. Lippincott Co. 1988 pp 1-19

2. Antman EM Beamer AD Cantillon C McGowan N Friedman PL: Propafenone for suppression of refractory symptomatic atrial fibrillation. (abstract) Circulation 1987;76(suppl IV):IV-68

3. Hammill S Wood D Sugrue D Gersh B Osborn M Holmes D: Propafenone for chronic treatment of paroxysmal atrial fibrillation. (abstract) Circulation 1985;72(suppl III):III-171

4. Kerr CR Mason MA Chung DC: Propafenone: An effective drug for prevention of recurrent atrial fibrillation. (abstract) Circulation 1985;72(suppl III):III-171

5. Oral flecainide for prophylaxis of paroxysmal atrial fibrillation

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3